Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture

ABSTRACT

Methods and materials for culturing primate-derived primordial stem cells are described. In one embodiment, a cell culture medium for growing primate-derived primordial stem cells in a substantially undifferentiated state is provided which includes a low osmotic pressure, low endotoxin basic medium that is effective to support the growth of primate-derived primordial stem cells. The basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate selected from the group consisting of feeder cells and an extracellular matrix component derived from feeder cells. The medium further includes non-essential amino acids, an anti-oxidant, and a first growth factor selected from the group consisting of nucleosides and a pyruvate salt.

This application is a National stage filing of PCT/US98/22619, filedOct. 23, 1998, which is a continuation in part of Ser. No. 08/956,684,filed Oct. 23, 1997, now abandoned; Ser. No. 08/961,628, filed Oct. 31,1997, now abandoned; Ser. No. 08/961,629, filed Oct. 31, 1997, nowabandoned; and Ser. No. 08/990,560, filed Dec. 15, 1997, now abandoned.

1 BACKGROUND OF THE INVENTION

1.1 Field of the Invention

The present invention relates to the field of stem cell culture mediaand to methods for culturing such cells. More particularly, the presentinvention provides methods and materials for culturing primate-derivedprimordial stem cells in a substantially undifferentiated state with andwithout a feeder layer. The present invention has applications in theareas of cell culture, tissue transplantation, drug discovery, and genetherapy.

1.2 The Related Art

Stem cells are cells capable of differentiation into other cell typeshaving a particular, specialized function (“fully differentiated” cells)or other types of stem cells which are capable of differentiation into amore narrow range of cell types (“pluripotent” cells). Stem cells havingthe ability to differentiate into any type of cell, i.e., pluripotent orfully differentiated, are called “totipotent”. Such cells are alsoreferred to as “primordial stem cells”. There has been great interest inisolating and growing primordial stem cells from primates, especiallyfrom humans, as such primordial stem cells could provide a supply ofreadily available cells and tissues of all types for use intransplantation, drug discovery, and gene therapy in humans.

Methods for isolating and growing primordial stem cells from primateshave been described. Procedures for isolating and growing humanprimordial stem cells are described in co-pending U.S. patentapplication Ser. No. 08/829,372. Procedures for obtaining Rhesus monkeyand other non-human primate primordial stem cells are described inco-pending U.S. patent applications Ser. Nos. 08/376,327; 08/591,246;08/665,217; and WO 96/22362. Each of these patent applications isincorporated herein by reference in its entirety and for all purposes.In addition, methods for isolating Rhesus monkey primordial stem cellsare described in Thomson et al. (1995 Proc. Natl. Acad. Sci. USA92:7811-7848) also incorporated herein by reference in its entirety andfor all purposes.

Unfortunately, current methods for growing primordial stem cells derivedfrom primates in culture have not been as clearly defined as, and arerelatively inefficient compared with, methods for culturing primordialstem cells for other species such as mouse. For example, current methodsof culturing primate-derived primordial stem cells require a feederlayer that complicates and slows the process of cell cultivation. Inaddition, the formulation of an optimal culture media for propagatingundifferentiated totipotent primate-derived primordial stem cellsremains to be determined.

In particular, it is desirable to maintain cultures of totipotentprimordial stem cells for extended periods or indefinitely. The abilityto maintain cultures of undifferentiated, totipotent, primate-derivedprimordial stem cells for long periods facilitates the use of such cellsfor therapeutic purposes. Moreover, it would be desirable to growcultures of substantially undifferentiated primate-derived primordialstem cells for periods sufficient to allow the production ofprimate-derived primordial stem cells having multiple geneticmodifications for the production of tissues and for gene therapy.

2 SUMMARY OF THE INVENTION

The present invention provides methods and reagents for culturingprimate-derived primordial stem cells in a substantiallyundifferentiated state. The methods and materials described hereinprovide improved culturing conditions that allow the preparation ofprimate-derived primordial stem cells having single or multiple geneticmodifications. Such modified cells have important applications in genetherapy and tissue transplantation/implantation therapies.

In one aspect, the present invention provides a cell culture medium forgrowing primate-derived primordial stem cells in a substantiallyundifferentiated state. In one embodiment, the cell culture medium ofthe invention comprises a low osmotic pressure, low endotoxin basicmedium that is effective to support the growth of primate-derivedprimordial stem cells. This basic medium is combined with a nutrientserum effective to support the growth of primate-derived primordial stemcells and a substrate selected from the group of feeder cells, such asmouse embryo fibroblast cells and STO cells, and an extracellular matrixderived from the feeder cells. The medium further includes non-essentialamino acids, an anti-oxidant (for example, β-mercaptoethanol), and,optionally, a first growth factor selected from the group consisting ofnucleosides and a pyruvate salt.

In more specific embodiments, the basic medium of the cell culturemedium has an osmotic pressure of less than about 300 mOsm/kg. Stillmore specific embodiments are those for which the basic medium has anosmotic pressure of about 280 mOsm/kg. Yet other embodiments of the cellculture medium of the present invention include those for which thebasic medium has an endotoxicity of less than about 0.1 endotoxin unitsper ml. More specific embodiments for which the endotoxicity of thebasic medium is less than about 0.1 endotoxin units per ml are thoseembodiments for which the endotoxicity of the base medium is about 0.03endotoxin units per ml.

In other embodiments the cell culture medium of the invention furtherincludes a second growth factor. In a preferred embodiment, the secondgrowth factor is selected from the group consisting of: Anti-IL-8,Anti-TGF-β5, Anti-BDNF, Anti-TNF-β, Anti-VEGF, Anti-TGF-β, IL-11, IL-6,IL-6+soluble IL-6 receptor, IL-1α, IL-1β, LIF, Anti-HB-EGF, IL-17,TFG-β-1 LAP, MCP-1, bFGF, FGF-4, PDGF Soluble Receptor A, dexamethasoneand Forskolin.

Suitable growth factors for use in the present invention can bedetermined using a method for screening for growth factors that isprovided in another aspect of the present invention. According to oneembodiment of this aspect of the invention, primate-derived primordialstem cells are grown using a cell culture medium of the presentinvention in the presence of a putative growth factor. A determinationis made as to whether the putative growth factor enhances the growth ofundifferentiated primate-derived primordial stem cells. Substances thatenhance the growth of primate-derived primordial stem cells areclassified as growth factors.

In another aspect, the present invention provides a culture of primateprimordial cells, comprising at least one primate-derived primordialstem cell in fluid contact with the cell culture medium of theinvention. Such cells can be human- or Rhesus-derived primordial stemcells, for example.

In still another aspect, the present invention provides methods forproducing primate cell lines having one or more genetic modifications.According to one embodiment of this aspect of the present invention,primordial stem cells are grown using a cell culture medium of theinvention. A first gene or nucleic acid is introduced into, or a firstgene is modified in, these cells and a first clone population isderived. In a further embodiment, a second gene or nucleic acid isintroduced into, or a second gene is modified in, the cells of the firstclone population and a second clone population is derived. In someembodiments, the primordial stem cells are derived from human embryoniccells. In other embodiments the primordial stem cells are PSC43 cells,an aneuploid variant of Rhesus embryonic stem cells that is capable ofgrowing in a feeder-free cell culture as described hereinbelow. Thiscell line has been found effective for screening for growth factors forcell culture media.

These and other aspects and advantages will become apparent when theDescription below is read in conjunction with the accompanying Examples.

3 DESCRIPTION OF SOME EMBODIMENTS OF THE INVENTION

The present invention provides methods and materials for culturingprimate-derived primordial stem cells in a substantiallyundifferentiated state and for identifying and quantifyingundifferentiated primate-derived primordial stem cells. In addition, thepresent invention also provides screens for discovering substances thataccelerate or retard the differentiation of such cells. In addition tothe many benefits deriving from access to primate-derived primordialstem cells, the methods and materials provided by the present inventioncan be applied to produce primordial stem cells having single ormultiple genetic modifications. Primate-derived primordial stem cellshaving such serial modifications have important applications, especiallywith respect to applications where euploid primate cells having geneticmodifications are useful or required. Examples of such applicationsinclude, but are not limited to, the development of cell-based models,for primate, especially human, diseases, as well as the development ofspecialized tissues for transplantation to treat genetic diseases.

3.1 Definitions

The following terms will be defined as provided in this Section 3.1unless otherwise stated. All other terminology used herein will bedefined with respect to its usage in the particular art to which itpertains unless otherwise noted.

3.1.1 Basic Medium

Basic Medium refers to a solution of salts and nutrients that iseffective to support the growth of primate-derived primordial stem cellsin culture.

3.1.2 Conditioned Medium

Conditioned Medium refers to a growth medium that is furthersupplemented with soluble factors derived from feeder cells.

3.1.3 Embryonic Germ Cells

Embryonic Germ Cells or EG Cells are cells derived from the primordialgerm cells of an embryo or fetus that are destined to give rise to spermor eggs.

3.1.4 Embryonic Stem Cells

Embryonic Stem Cells or ES Cells are cells obtained from morula orblastocyst stages of a pre-implantation stage embryo.

3.1.5 Extracellular Matrix

Extracellular Matrix or Defined Matrix as used for the purposes ofdescribing the present invention refers to one or more substances thatprovide substantially the same conditions for supporting cell growth asprovided by the surfaces of feeder cells.

3.1.6 Feeder Cells

Feeder Cells as used for the purposes of describing the presentinvention refers to non-primordial stem cells on which primate-derivedprimordial stein cells are plated, which non-primordial stem cellsprovide a milieu conducive to the growth of the plated primate-derivedprimordial stem cells.

3.1.7 Growth Factor

Growth Factor as used for the purposes of describing the presentinvention refers to a substance that is effective to promote the growthof primordial stem cells that is not otherwise a component of theconditioned medium. Such substances include, but are not limited to,cytokines, chemokines, small molecules, neutralizing antibodies, andproteins.

3.1.8 Low Osmotic Pressure Medium

Low Osmotic Pressure Medium refers to a solution having an osmoticpressure of less than about 300 milli-osmols per kilogram (“mOsm/kg”).

3.1.9 Non-essential Amino Acids

Non-essential Amino Acids refers to the amino acids L-alanine,L-asparagine, L-aspartic acid, L-glutamic acid, glycine, L-proline, andL-serine.

3.1.10 Primordial Stem Cell

Primordial Stem Cell refers to either an embryonic stem cell or anembryonic germ cell as defined herein.

3.1.11 Primate-derived Primordial Stem Cell

Primate-derived Primordial Stem Cell refers to a primordial stem cellthat is obtained from a primate species, including humans and monkeys,including genetically modified primordial stem cells obtained from aprimate.

3.1.12 Pluripotent

Pluripotent refers to cells that are capable of differentiating into oneof a plurality of different cell types although not necessarily all celltypes. One example of pluripotent cells are bone marrow stem cells whichare capable of differentiating into various blood cell types such aslymphocytes and red blood cells but not nerve cells. Thus, it will berecognized that while all totipotent cells are pluripotent, not allpluripotent cells are totipotent.

3.1.13 Substantially Undifferentiated

Substantially Undifferentiated refers to a group of primate-derivedprimordial stem cells of which at least about 50% are in anundifferentiated, totipotent, state.

3.1.14 Totipotent

Totipotent refers to cells that are capable of differentiating into anycell type including pluripotent and fully differentiated cells (i.e.,cells no longer capable of differentiation into various cell types),such as, without limitation, bone marrow stem cells, cardiac musclecells, astrocytes, or connective tissue cells.

3.2 Growing and Maintaining Primate-derived Primordial Stems Cells in aSubstantially Undifferentiated State

As described in Sections 3.2.1 and 3.2.2 below, the present inventionprovides cell culture media, growth factors, and methods for growing andmaintaining cultures of primate-derived primordial stem cells in asubstantially undifferentiated state that provides for the growth andmaintenance of totipotent primate-derived primordial stem cells forperiods longer than heretofore available. The improved cell culturemedia of the invention can also be used to screen for additional growthfactors and useful combinations of growth factors as described inSection 3.3 below. As discussed in Section 3.4 below, the ability togrow primate-derived primordial stem cells in a substantiallyundifferentiated, totipotent state using the improved cell culturemedia, growth factors, and methods provided herein provides importantbenefits including the ability to produce primate-derived primordialcell lines having single or multiple genetic modifications havingimportant therapeutic applications.

3.2.1 Cell Culture Media for Growing and Maintaining Primate-derivedPrimordial Stem Cells in a Substantially Undifferentiated State

In one aspect, the present invention provides improved cell culturemedia for growing and maintaining primate-derived primordial stem cellsin a substantially undifferentiated state. In one embodiment, the cellculture media of the present invention includes a low osmotic pressure,low endotoxin basic medium that is effective to support growth ofprimate-derived primordial stem cells; a nutrient serum effective tosupport growth of primate-derived primordial stem cells; a substrateselected from the group consisting of feeder cells, such as mouse (orother species) embryo fibroblast cells and STO cells, and anextracellular matrix derived from such feeder cells; non-essential aminoacids; an anti-oxidant (reducing agent); and a first growth factorselected from the group consisting of nucleosides and a pyruvate salt.

In one particular embodiment, the osmotic pressure of the basic mediumis less than about 300 milli-osmols per kilogram (“mOsm/kg”), and, moreparticularly, less than about 280 mOsm/kg. In one embodiment, theosmotic pressure of the basic medium is about 280 mOsm/kg. Theendotoxicity, as measured in endotoxin units per milliliter (“eu/ml”) isless than about 0.1 eu, and, in a more particular embodiment, less thanabout 0.05 eu/ml. In a still more particular embodiment, theendotoxicity of the basic medium is less than about 0.03 eu/ml. In oneparticular embodiment, the endotoxicity of the basic medium is about0.03 eu/ml. Methods for measuring endotoxicity are known in the art. Forexample, a preferred method is described in the “Guideline on Validationof the Limulus Amebocyte Lysate Test as an End-product Endotoxin Testfor Human and Animal Parental Drugs, Biological Products and MedicalDevices” published by the U.S. Department of Health and Human Services,FDA, December 1987.

The nutrient serum can be any serum or serum-based solution thatsupplies nutrients effective to maintain the growth and viability ofprimate-derived primordial stem cells. Examples of such serum include,without limitation, fetal bovine serum (“FBS”) and fetal calf serum(“FCS”). In one embodiment, the serum is FBS. In a more particularembodiment, the FBS is provided in a concentration of between about 25%and about 1%. In a more particular embodiment, the FBS is provided in aconcentration of between about 20% and about 2.5%. In as still moreparticular embodiment, the concentration of FBS in the cell culturemedium is 20%. In another embodiment, the concentration of FBS is 2.5%.

Other embodiments of the cell culture media of the present inventioninclude those for which a first growth factor includes one or morenucleosides. In more specific embodiments, the nucleoside(s) areselected from the group consisting of adenosine, cytosine, guanine,uridine and thymidine. Still more particular embodiments include thosefor which the nucleoside(s) selected are in about equal concentrations.More specific embodiments include those for which the concentration ofnucleoside(s) included in the cell culture media of the invention isbetween about 0.1 μM and about 30 μM, and, more particularly, the mediaconcentration is between about 0.3 μM and about 10.0 μM. In a still moreparticular embodiment, the concentration of nucleoside(s) is betweenabout 0.5 μM and about 5.0 μM. In one embodiment, the concentration ofnucleoside(s) is about 0.1 μM. In still other embodiments, the firstgrowth factor can be a pyruvate salt, such as sodium pyruvate or anotherpyruvate salt that is effective to maintain and/or enhance cell growthin a substantially undifferentiated state such as, for example,potassium pyruvate. The pyruvate salt can be combined with one or moreof the above-described nucleosides. In one embodiment, the pyruvate saltis provided in a concentration of 1mM.

In some embodiments a second growth factor (as defined in Section 3.1.7)is also provided, again, to assist in the maintenance of cultures ofprimate-derived primordial stem cells in a substantiallyundifferentiated state. The identities and effective concentrations ofsuch second growth factors can be determined using the methods describedin Section 3.3 below or using techniques known to those of skill in theart of culturing cells. In one embodiment, a second growth factor isincluded with the cell culture media of the invention which secondgrowth factor is selected from the group consisting of: Anti-IL-8,Anti-TGF-β5, Anti-BDNF, Anti-TNF-β, Anti-VEGF, Anti-TGF-β, IL-11, IL-6.IL-6+soluble IL-6 receptor, IL-1α, IL-1β, LIF, Anti-HB-EGF, IL-17,TFG-β-1 LAP, MCP-1, bFGF, FGF-4, PDGF Soluble Receptor A, glucocorticoid(e.g., dexamethasone) and Forskolin. The second growth factor can be oneor more of the above-listed substances as well as other growth factorsthat can be easily identified.

In one embodiment, the second growth factor is forskolin ([3R-(3α, 4αβ,5β, 6β, 6aα, 10α, 10αβ, 10bα)]-5-(acetyloxy)-3-ethenyldodecahydro-6, 10,10b-trihydroxy-3, 4a, 7, 7, 10a-pentamethyl-1-H-naphtho[2,1-b]pyran-1-one). In one embodiment, the forskolin is added to the cellculture medium of the invention to achieve a concentration of less thanabout 30 μM. In a more particular embodiment, the concentration offorskolin in the cell culture medium of the invention is between about 5μM and about 15 μM, and, more particularly, between about 8 μM and about12 μM. In one embodiment, the concentration of forskolin added to thecell culture medium of the invention is about 10 μM. In anotherembodiment, the concentration of forskolin is about 20 μM.

In another embodiment, the second growth factor is selected from thegroup consisting of “basic” FGF (“bFGF”) and/or FGF-4, alone or incombination with human insulin, anti-TGF-β-1 antibody, and EGF. In oneembodiment, the concentration of bFGF in the cell culture medium isabout 5 nanograms/milliliter (“ng/ml”), either alone or combined withhuman insulin. When combined with bFGF, the concentration of humaninsulin is about 8 μg/ml. In those embodiments for which EGF is added tothe cell culture medium of the invention, the concentration of EGF isabout 0.1 ng/ml.

The cell culture media of the invention also includes an anti-oxidant(reducing agent), such as β-mercaptoethanol. In a preferred embodiment,the β-mercaptoethanol has a concentration of about 0.1 mM. Otheranti-oxidants such as monothioglycerol or dithiothreitol (“DTT”), aloneor in combination, can be used to similar effect. Still other equivalentsubstances will be familiar to those of skill in the cell culturingarts.

In addition to the above-described components, the cell culture media ofthe invention further includes a substrate selected from the groupconsisting of feeder cells, such as mouse (or other species) embryofibroblast cells and STO cells, and an extracellular matrix derived fromsuch feeder. In one embodiment, mouse embryo fibroblasts obtained fromdissection of 13.5-day-old CF-1 strain mice are used. Other suitablefeeder cell lines will be familiar to those of skill in the cell cultureart. If feeder cells are used, as opposed to extracellular matrix, thecells can be mitotically inactivated (e.g., by irradiation orchemically) to prevent further growth and seeded on plates. Theprimate-derived primordial stem cells can then be grown on the plate inaddition to the feeder cells. Alternatively, the feeder cells can befirst grown to confluence and then inactivated to prevent furthergrowth. It will be appreciated that such an approach has the advantageof simplifying the management of the cell culture as the growth of onlyone set of cells, the primordial stem cells, need only be monitored.

Not wishing to be bound to any theory, it is believed that the use ofsuch feeder cells, or an extracellular matrix derived from such feedercells, provides one or more substances necessary to promote the growthof primate-derived primordial stem cells and/or prevent or decrease therate of differentiation of such cells. Such substances are believed toinclude membrane-bound and/or soluble cell products that are secretedinto the surrounding medium by the cells. Thus, those of skill in thecell culturing arts will recognize that additional cell lines can beused with the cell culture medium of the present invention to equivalenteffect and that such additional cell lines can be identified usingstandard methods and materials. In addition, those of skill will alsorecognize that one or more substances produced by the feeder cells, orcontained in the extracellular matrix, can be identified and added tothe cell culture medium of the invention to obviate the need for suchfeeder cells and/or such extracellular matrix.

In one particular embodiment of the invention, the preparation of whichis described in detail in Section 4.1 below, a cell culture mediumprovided by the present invention includes the components andconcentrations set forth in Table 1.

TABLE 1 Medium Component Identity, Amount, and Supplier Basic Medium 280mOsm/kg Dulbecco's Modified Eagle Medium (DMEM, 4500 mg glucose perliter, with L-glutamine (GIBCO)) Nutrient Serum 20% fetal bovine serum(HyClone) Substrate Mouse embryo fibroblasts obtained from 13.5-day-oldembryos of CF-1 strain mice Non-essential Amino Acids 0.1 mMnon-essential amino acid stock solution (GIBCO)  β-mercaptoethanol 0.1mM β-mercaptoethanol (Sigma) First Growth Factor a final mediumconcentration of 1 μM each of adenosine, guanosine, thymidine, cytidine,and uridine (Sigma) and 1 mM sodium pyruvate (Sigma)  This solutionincludes L-alanine (8.9 mg/l), L-asparagine monohydrate (15 mg/l),L-aspartic acid (13.3 mg/l), L-glutamic acid (14.7 mg/l), glycine (7.5mg/l), L-proline (11.5 mg/l), and L-serine (10.5. mg/l).

3.2.2 Growing Primate-derived Primordial Stem Cells Using the CellCulture Media of the Invention

In another aspect, the present invention provides methods for growingprimate-derived primordial stem cells in a substantiallyundifferentiated state and cultures of such cells in such cell culturemedia described above in Section 3.2.2. Detailed examples of the methodsprovided by the present invention can be found in Sections 4.1 and 4.2below.

The primate-derived primordial stem cells to be cultured can be obtainedusing known methods and materials. Procedures for isolating humanprimordial stem cells are described in co-pending U.S. patentapplication Ser. No. 08/829,372, filed on Mar. 31, 1997. Procedures forobtaining Rhesus monkey and other non-human primate primordial stemcells are described in co-pending U.S. patent application Ser. Nos.08/376,327, filed Jan. 20, 1995; 08/591,246, filed Jan. 18, 1996; WO96/22362, published Jul. 25, 1996; 08/665,217, filed Jun. 14, 1996; and08/874,695, filed Jun. 13, 1997. Each of these patent applications isincorporated herein by reference in their entirety and for all purposes.In addition, methods for isolating Rhesus monkey primordial stem cellscan be found in Thomson et al. (1995 Proc. Natl. Acad. Sci. USA92:7844-7848) also incorporated herein by reference in its entirety andfor all purposes.

Once isolated, the primate-derived primordial stem cells are culturedusing the above-described conditioned medium using any of a variety oftechniques. In one embodiment, a container holds feeder cells in anon-conditioned medium. A matrix of lysed feeder cells is prepared usingstandard methods. One example of the preparation of such a matrix isprovided in Section 4.2 below. The primordial stem cells to be culturedare then added atop the matrix along with the conditioned medium.Alternatively, the primate-derived primordial stem cells can be grown onliving feeder cells using methods known in the cell culture arts. Thegrowth of the primordial stem cells is then monitored to determine thedegree to which the cultured cells have become differentiated. In oneembodiment, described in Section 4.2 below, a marker for alkalinephosphatase is used to ascertain which cells have differentiated. When asufficient number of cells have differentiated, or when the culture hasgrown to confluence, at least a portion of the undifferentiated cells ispassaged. The determination to passage the cells and the techniques foraccomplishing such passaging can be performed using standard techniques.

3.3 Screens for Growth Factors

In another aspect, the present invention provides screens fordetermining growth factors that promote or inhibit the differentiationof primate-derived primordial stem cells in culture. In one embodiment,an aneuploid variant of Rhesus 278.5 ES cells having 43 chromosomes,hereinafter referred to as “PSC43 cells”, is used as a primary screen toidentify substances that promote the growth of primate-derivedprimordial stem cells in a substantially undifferentiated state. In oneembodiment of the primary screen, the presence of increased alkalinephosphatase activity indicates that the substance being tested is agrowth factor. Substances that are found to produce statisticallysignificant promotion of the growth of PSC43 cells in anundifferentiated state can then be tested against normal primate-derivedprimordial embryonic stem cells. Substances found to be effective growthfactors for these cells are then tested in combinations to determine thepresence of any synergistic effects. Optionally, a secondary screen canbe employed to confirm growth factors identified by the primary screen.

In one embodiment, described in detail in Section 4.4.2, the screens areperformed on groups of PSC43 cells grown under four different growthconditions (alternatively, normal Rhesus, human or other primate-derivedprimordial stem cells can be used). A first growth condition (describedin Section 4.4.2.1) includes STO (or other suitable) feeder cells in themedium described in Section 3.2.1 above. A second growth condition(Section 4.4.2.2) includes growing cells under the same conditions asthe first growth condition, except that an extracellular matrix of STOor MEF cells is used in place of the feeder cells (see Section 3.2.1). Athird growth condition (Section 4.4.2.3) includes growing cells on a“defined matrix” that comprises one or more substances that approximatethe extracellular matrix of feeder cells. In one embodiment, the definedmatrix includes one or more substances selected from the groupconsisting of collagen II, heparan sulfate, and merosin. Still othersuitable substances can be determined using methods known in the cellculturing arts. A fourth growth condition (Section 4.4.2.4) includesgrowing cells under the same conditions as the first growth conditionwith the exception that 2.5% FBS is used in the nutrient serum insteadof 20% FBS.

In one embodiment, the level of expression of alkaline phosphatase isdetermined for each group of cells exposed to a particular putativegrowth factor using the methods described herein (see Section 4.2).Substances that are correlated with increased alkaline phosphataseexpression relative to unexposed control cells are considered to begrowth factors. In a particular embodiment, substances found to producean increase of alkaline phosphatase expression greater than about 20% ascompared with the control are considered growth factors.

In another embodiment, substances identified as growth factors in theprimary screen are tested in a secondary screen to determine thepresence or absence of a correlation between exposure of the cells tothe substance and a parallel increase in the expression of surfacemarkers associated with lack of differentiation such as telomerase(described below in section 4.7), stage-specific embryonic antigen-4(SSEA-4), stage-specific embryonic antigen-3 (SSEA-3) (both described byKannagi et al., EMBO J, 1983, 2(12):2355-61), TRA-1-60 antigen andTRA-1-81 antigen (both described by Andrews et al., Hybridoma, 1984,3(4) 347-61.

In such an embodiment, the cells are cultured as described in theprimary screen. The cells are then exposed to an antibody raised againstone or more of the surface marker(s) being screened, and/or the presenceor absence of telomerase expression in the exposed cells is determined(see Section 4.7). In some embodiments, the surface marker antibodiesare incubated with a second antibody coupled with a reporter such as afluorescent label so that cells expressing the appropriate antigenicmarker are rendered fluorescent. Labeled cells can then be sorted andcounted using standard methods, e.g., a fluorescence-activated cellsorter (“FACS”). The numbers of labeled and unlabelled cells can then becompared to determine the effect of the putative growth factor.Alternatively, following exposure to unlabelled cell surface markerantibodies, the cells can be exposed to a second antibody that isspecific for the cell surface marker antibody in an ELISA (Enzyme-LinkedImmunoSorbent Assay) format from which the number of cells expressingthe desired surface antigen can be quantitated calorimetrically or bymeasurement of fluorescence. Still other methods of quantitating cellsexpressing surface antigens will be familiar to those having skill inthe cell culture arts.

Substances identified as growth factors in the primary, and, optionally,secondary, screens are screened again using the same format as theprimary screen discussed above but wherein actual primate-derivedprimordial stem cells are used. Those substances that are confirmed tobe growth factors are then tested in combination (e.g., combinations oftwo or three substances) to determine the presence of any synergisticproperties among the growth factors. In addition, substances that maypromote differentiation or retard the growth of undifferentiated cellscan be identified. For example, antibodies directed to substances in thegrowth medium can be added to prevent those substances from interactingwith the cells being cultured.

One example of the use of the above-described techniques for determiningan optimized culture medium is provided in Section 4.5 below in whichalkaline phosphatase (AP) activity is used as marker forundifferentiated cells. There, PSC43 cells were grown using an STO-basedextracellular matrix in a medium that included DMEM with 4.5 g/Lglucose, 0.1 mM non-essential amino acids, 0.1 mM β-mercaptoethanol and20% fetal bovine serum. To this medium sodium pyruvate, adenosine,guanosine, thymidine, cytidine, uridine, phenol red dye, and HEPESbuffer were added to determine the effect of each substanceindividually. As described in detail in Section 4.2.1, it was determinedthat the addition of 1 mM sodium pyruvate to the medium resulted in anincrease in the amount of AP activity. In addition a final concentrationof 1 μM each of adenosine, guanosine, thymidine, cytidine and uridine tothe sodium pyruvate growth medium resulted in even more enhanced APactivity levels of PSC 43 cells at both the 11^(th) and 17^(th)passages. The use of anti-retinoic acid antibodies to deplete the growthmedium of retinoic acid also provided enhanced growth ofundifferentiated cells as measured by AP activity as described inSection 4.6.

Substances identified as promoters of undifferentiated cell growth usingthe above-described screening methods and materials are described inTable 2 below. Those having skill in the cell culture arts willrecognize that several factors identified as promoters ofundifferentiated cell growth are members of the IL-6 and LIF families ofcytokines. Such substances have been recognized as interacting withspecific receptors that heterodimerize with gp 130 to effect signaltransduction (Fourcin, et al., J. Biol. Chem., 271(20):11756-11760(1996)) and, thereby, maintenance of undifferentiated growth.Unfortunately, IL-6 and LIF-family receptors are highly speciesspecific; therefore, growth factors isolated from one species may notfunction with cell lines isolated from another species. However,anti-gp130 antibodies can also be used to effect signal transduction bygp130 (Wijdenes, et al., Eur. J. Immunol., 25:3474-3481). Thus, thepresent invention further includes methods and media for culturingprimate-derived primordial stem cells including anti-gp130 antibodies.

In another embodiment, the cell culture methods and materials of theinvention include a glucocorticoid, such as dexamethasone ((11β,16α)-9-fluoro-11, 17, 21-trihydroxy-16-methylpregna-1, 4,-diene-3,20-dione). In one embodiment, the dexamethasone is provided at aconcentration of between about 1.0 nanomolar (nM) and about 10.0 μM. Inone more particular embodiment, the concentration of dexamethasone isbetween about 1.0 nM and about 1.0 μM. In another particular embodiment,the concentration of dexamethasone is between about 1.0 nM and about 500nM. In still another embodiment, the dexamethasone is provided at aconcentration of between about 1.0 nM and about 100 nM. In yet anotherembodiment, the dexamethasone is provided at a concentration of about 10nM. In still other embodiments, the dexamethasone is combined with atleast one substance that is a member of the IL-1, IL-6, IL-11, or LIFfamilies of cytokines. In some embodiments, dexamethasone is combinedwith at least one of the following: IL-1β (at a concentration of about50 picograms/mi (pg/ml)), IL-6 (at a concentration of about 0.004micrograms/ml (μg/ml)), LIF (at a concentration of about 1.2 ng/mil),and IL-11 (at a concentration of about 1.0 ng/ml).

3.4 Applications of the Cell Culture Growth Media of the Invention

The improved cell culture media and methods for growing primate-derivedprimordial stem cells in a substantially undifferentiated state that isprovided by the present invention will be seen to be applicable to alltechnologies for which primate-derived cell lines are useful. Ofparticular importance is the use of the cell culture media and methodsof culturing primate-derived primordial stem cells provided by thepresent invention to create new primate primordial stem cell lineshaving single or multiple genetic modifications which application isdiscussed in Section 3.4.1. Cells produced using the media and methodsof the present invention can be mounted on surfaces to form biosensorsfor drug screening (see Section 3.4.2). In addition the observation thatprimate primordial stem cells are telomerase positive can be used todetermine the engraftment potential of primordial stem cells, bothprimate-derived and non-primate-derived, as described in Section 3.4.3.

3.4.1 Creation of Primate-derived Primordial Stem Cells Cell LinesHaving Multiple Genetic Modifications

In one aspect, the methods and culture media of the present inventionare used to produce primate-derived primordial stem cells having singleor multiple genetic modifications. Genetic alteration of cells isdesirable for many reasons, such as providing modified cells for genetherapy and replacement tissues for grafting or implantation (e.g., toavoid host rejection of the cells).

According to one embodiment of this aspect of the present invention,primordial stem cells are grown using the culture media and methodsdescribed in Section 3.2.1 above. A first gene is modified in, orintroduced into, at least one of the cells of the cell culture and fromthe resulting culture a first clone population of modified primordialstem cells is derived. The first clone population can be grown in theculture media of the invention allowing the establishment of a cell linewith the desired genetic modification. If further genetic modificationsare needed, a second gene is modified in, or introduced into, at leastone cell of the first clone population to produce a second clonepopulation having first and second genetic modifications. Alternatively,the first and second genetic modifications can be introduced into thesame primordial stem cell with subsequent simultaneous screening forboth modifications (i.e., circumventing the need to isolate a firstclone population); however, the preferred procedure is a stepwiseprocedure.

The methods used to perform the genetic modifications to the cells canbe any of those known in the molecular biological arts for makinggenetic transforms. Such methods include, but are not limited to, theuse of positive-negative selector vectors as described in U.S. Pat. Nos.5,464,764; 5,487,992; 5,627,059; and 5,631,153 to Capecchi, et al.; andU.S. patent application Ser. No. 08/781,559. In addition, yeastartificial chromosomes (YACs) can be employed to perform geneticmodifications as described in U.S. patent application Ser. Nos.08/597,532; 08/397,547; 08/187,161; 08/276,565; 08/375,482; 08/485,505;and 08/372,482. Furthermore, isogenic DNA constructs can be used withthe primordial stem cells cultured using the methods and materialsprovided by the present invention as described in U.S. patentapplication Ser. No. 08/563,138. Still other methods include thosedescribed in U.S. Pat. No. 5,591,625 to Gerson, et al. for thepreparation stem cells capable of augmented expression of certain geneproducts, signal transduction molecules, cell surface proteins and thelike for therapeutic applications. U.S. Pat. No. 5,583,016 describesmethods for introducing a recombinant gene for the RNA component oftelomerase into cells and GB2317891 describes methods for increasing theamount of human telomerase reverse transcriptase (hTRT) in a cell, forexample, by introducing the reverse transcriptase subunit of telomeraseinto cells. These patents and patent applications are incorporatedherein by reference in their entirety and for all purposes.

As is apparent to one of ordinary skill in the art, altered expressionof gene products can be achieved by modifying the coding sequence of agene product or altering flanking regions of the coding sequence. Thus,as used herein, the term “genetic modification” includes alterations tothe sequence encoding a gene product, as well as alterations to flankingregions, in particular the 5′ upstream region of the coding sequence(including the promoter). Similarly, the term “gene” encompasses thecoding sequence and regulatory sequences that may be present flankingthe coding sequence, as well as other sequences flanking the codingsequence. In addition, as is known in the art, genetic modifications canbe achieved by introducing a nucleic acid that does not necessarilycomprise the entire gene sequence into the cell, e.g., by introducing anucleic acid that can be inserted into the genome by recombination.

In one embodiment of the invention in which genetically-modifiedprimate-derived primordial stem cells are to be use for implantationinto a patient, e.g., to treat Parkinson's disease, the primate-derivedprimordial stem cells are modified genetically to express Fas ligand(also known as CD95). Cells expressing the Fas ligand are known toinduce apoptosis in T cells; thereby becoming immunologically privileged(Griffith, et al., Science, 270:1189-1192 (1995); Bellgrau, et al.,Nature, 377:630-632 (1995)). In one embodiment, the present inventionprovides primate-derived primordial stem cells having multiple geneticmodifications wherein at least one of the modifications is theexpression of Fas ligand. In another embodiment, the modifiedprimate-derived primordial stems cells are differentiated into adifferent cell type using, e.g., a differentiation promoter listed inTable 3 below.

3.4.2 Biosensors Comprising Primate-derived Primordial Stem Cells

In another aspect, cells cultured and/or modified using the materialsand methods provided by the present invention are mounted to supportsurfaces to screen for bioactive substances. In one embodiment, thecells are coupled with a substrate such that electrophysiologicalchanges in the cells in response to external stimuli can be measured,e.g., for use as a high-throughput screen for bioactive substances. Inone more particular embodiment, the cells have been transfected with DNAthat targets, expresses, or knocks-out specific genes or gene productsin the cell. By providing such chip-mounted cells coupled with measuringdevices, such as a computer, many compounds can be screened rapidly andaccurately. The biosensors could also be coupled to the measuring devicein arrays for large-scale parallel screening.

In another embodiment, a reporter gene is incorporated into the DNA of aprimordial stem cell that is functionally coupled with a copy of a geneassociated with a particular disease state (e.g., BRCA-1 in the case ofbreast cancer) using the methods described in Section 3.4.1 above. Inone embodiment, the reporter is sensitive to both transcription andpost-transcriptional events. The primordial stem cells are allowed todifferentiate such that the differentiated progeny each contain one copyof the disease gene/reporter construct. The cells are then screenedagainst putative therapeutic agents. This allows the correlation of geneexpression and responsiveness to a potential therapeutic agent with thestate of differentiation of the cell. By suitable selection of thereporter, such a screening strategy can be executed with theabove-described high-throughput biosensors. Still other applications ofbiosensors such as discussed herein will be apparent to those havingskill in the art.

3.4.3 Prediction of Stem Cell Engraftment Potential of Primate-derivedPrimordial Stem Cells

In yet another aspect, the determination of telomerase activity as amarker for cell differentiation as described in Section 4.7 below isused to determine the engraftment potential of primate-derivedprimordial stem cells cultured using the methods and materials of thepresent invention. In one embodiment, primordial stem cells culturedusing the methods and materials of the invention are allowed todifferentiate, or, alternatively, induced to differentiate, to producepluripotent daughter cells such as hematopoietic stem cells for use intransplantation. Induction of differentiation can be performed usingagents effective to induce differentiation such as retinoic acid. Thecells may be genetically unaltered or may be genetically modified usingthe methods described in Section 3.4.1 above. The pluripotent daughtercells identified as having strong telomerase expression can bespecifically isolated and used for transplantation or further culturingand/or modification as described above.

In another embodiment, the use of the cell culture medium and methods ofthe present invention to provide cultures of unmodified and modifiedprimate primordial stem cells is used to screen for substances thatimprove the monitoring of stem cells or the collection of stem cells.For example, putative engraftment enhancing substances can be added to acell culture grown using the methods described above. Substances thatincrease telomerase expression compared to a control cell culture thatlacks the putative enhancing substance are identified as engraftmentpromoters or enhancers.

4 EXAMPLES

The following Examples are provided to illustrate certain aspects of thepresent invention and to aid those of skill in the art in practicing theinvention. These Examples are in no way to be considered to limit thescope of the invention in any manner.

4.1 Growth of Undifferentiated Primate-derived Primordial Stem Cells

This example illustrates a method for growing primate-derived primordialstem cells on a fibroblast feeder layer with a reduced rate ofdifferentiation.

Conditioned medium for growing ES cells was prepared using the followingprocedure. Mouse embryonic fibroblasts (“MEFs”), derived from dissectionof 13.5-day-old embryos of CF-1 strain mice, were grown to confluence inthe presence of a growth medium (hereinafter called “ES medium”)prepared from 20% fetal bovine serum (HyClone), 280 osmolal Dulbecco'sModified Eagle Medium (DMEM, 4500 mg glucose per liter, with L-glutamine(GIBCO)), 0.1 mM β-mercaptoethanol (Sigma), 0.1 mM non-essential aminoacid stock (GIBCO), 1 mM sodium pyruvate (GIBCO), and a final mediumconcentration of 1 μM each of adenosine, guanosine, thymidine, cytidine,and uridine (Sigma). About 0.25 ml of ES medium was provided for eachsquare centimeter of tissue culture dish surface area used for growingthe MEFs (i.e., about 0.25 ml ES medium/cm²). When the MEFs reachedconfluence, the ES medium was collected and filter-sterilized (0.2micron filter). This medium was termed “conditioned ES medium”. Theconditioned ES medium was used immediately or frozen at about −80° C.until needed.

A feeder layer was prepared from irradiated MEFs by exposing MEFssuspended in a 15 ml tube containing 10 ml of ES medium to about3,000-4,000 rads of_-radiation using a Torrex 140D model X-ray machine.After irradiation, the cells were pelleted at 1,000 rpm for 5 minutes atroom temperature in a Beckman TJ-6 tabletop centrifuge. The ES mediumwas removed from the pelleted cells and the cells were re-suspended infresh ES medium. The irradiated cells were then plated in gelatinizedtissue culture plates at a density of approximately 5×10⁴ cells/cm².

Rhesus monkey ES cells, isolated as described by Thomson, et al. (1995Proc. Natl. Acad. Sci. USA 92:7844-7848), were plated onto the feederlayer and fresh ES medium was added to the plated cells. Colonies ofundifferentiated Rhesus ES cells were detached from a feeder dish byincubating the dish with 1X 14190 D-PBS (GIBCO/BRL) containing 0.5 mMEDTA (Sigma) at room temperature for 2-5 minutes. Individual colonies ofRhesus ES cells were isolated using a small-bore pipette and transferredto an irradiated, fibroblast-coated 35 mm² tissue culture dishcontaining 2.5 ml of conditioned ES medium.

The Rhesus ES colonies were gently dispersed into small clumps using apipette (3-5 cells/clump) and transferred to a sterile 15 ml tube andpelleted at 1,000 rpm for about 5 minutes at room temperature using aBeckman TJ-6 tabletop centrifuge. The ES medium was removed, and thecells were re-suspended in 2.5 ml of fresh ES medium and transferred toa well containing a feeder layer. The ES medium was refreshed every 24hours. The cells were passaged when the colonies became large and priorto observable indications of differentiation such as the disappearanceof compact colonies of cells having a high nucleus-to-cytoplasm ratioand prominent nucleoli.

The Rhesus ES cells grown using the above-described method showed a muchhigher degree of undifferentiation than was observed when otherprocedures were used to grow such cells. A significant portion of theRhesus ES cells remained undifferentiated as judged by both themorphology and the continued surface expression of the enzyme alkalinephosphatase (AP), as determined by the method described in Section 4.2below. The cells were also capable of repeated passage under the samegrowth conditions.

4.2 Growth of Rhesus-derived ES Cells Without a Feeder Layer

PSC43 cells were grown using the above-described conditioned medium on afibroblast matrix that was prepared by seeding either MEFs or SIM mouseembryo-derived thioguanine-and ouabain-resistant (STO) fibroblasts(ATCC) into gelatinized tissue culture wells (1.0% weight/volume) 3-4days prior to use. The fibroblasts (MEF or STO) were plated at a lowdensity (approximately 1.3×10³ cells/cm²) and grown to confluence overthree to four days. At confluence, the fibroblasts were lysed in situ.The growth medium was removed from the wells and the wells were rinsedtwice with sterile 1X 14190 Dulbecco's Phosphate-Buffered Saline(D-PBS). A volume of freshly prepared lysis buffer (0.5% Triton-X100,3.5 μl ammonium hydroxide (NH₄OH), and D-PBS for a total volume of 10ml) sufficient to cover the cells of the matrix was added to the testwells. The cells were incubated with the lysis buffer at roomtemperature for about 10 minutes, at which time the lysis buffer wasremoved from the wells and the wells were rinsed three times with 1X14040 D-PBS (Gibco-BRL; D-PBS containing 0.1 g/L anhydrous CaCl₂ and 0.1g/L MgCl₂-6H20).

4.2.1 Supplementary Factors For Feeder-free Growth of Rhesus-derived ESCells

PSC 43 cells were grown and maintained on tissue culture dishes coatedwith extracellular matrix made by lysing confluent primary mouseembryonic fibroblasts (MEF) as described above. The initial basic growthmedium was DMEM with 4.5 g/L glucose, 0.1 mM non-essential amino acids,0.1 mM β-mercaptoethanol and 20% fetal bovine serum. The above-describedbasic growth medium was supplemented with the following substances:sodium pyruvate, adenosine, guanosine, thymidine, cytidine, uridine,phenol red dye, and HEPES buffer. The cells were cultured in the mediaso supplemented at media volumes corresponding to approximately one-halfthe total cell surface area with re-feedings every 24-48 hours, for 7days. AP activity was then measured as described in Section 4.3.

The addition of 1 mM sodium pyruvate to the medium resulted in anincrease in the amount of AP activity. The further addition of a finalconcentration of 1 μM each of adenosine, guanosine, thymidine, cytidineand uridine to the sodium pyruvate growth medium resulted in even moreenhanced AP activity levels of PSC 43 cells at both 11 and 17 passagenumbers. Removal of phenol dye or the addition of HEPES buffer had noeffect on AP measurements.

The use of media having reduced endotoxin levels (about 0.03 endotoxinunits/ml) also showed beneficial properties. Furthermore, the use ofDMEM having a reduced osmolarity of 280 mOsm/kg also provided enhancedgrowth conditions. R366.4 Rhesus embryonic stem cells (Thomson andMarshall, “Primate Embryonic Stem Cells”; Current Topics inDevelopmental Biology 38:133-164) grown in a 280 mOsm/kg medium showedenhanced AP activity compared to cells of the same lineage grown intypical medium having a osmolarity of 330-340 mOsm/kg. In addition,optimal cell density for plating the PSC 43 cells was determined to be1.3-2.2×10⁴ cell/cm².

4.3 Quantitation of Undifferentiated Primate-derived Primordial StemCell Propagation

This example illustrates a method for quantitating the proliferation ofundifferentiated primordial stem cells by measuring the degree ofalkaline phosphatase (“AP”) activity of such cells.

Rhesus or PSC43 cells were grown using the methods described in Sections4.1 and 4.2. The medium was removed from the cells by aspiration and thecells were washed with 1 ml of phosphate-buffered saline (“PBS”). About1 ml of the AP substrate, 4-methylumbelliferyl phosphate (“4-MUP”), at aconcentration of about 0.2 mM in serum-free DMEM medium was added to thecells. The cells were incubated at 37° C. for between about 1 hour andabout 2 hours at which time the amount of fluorescent product wasmeasured using a CYTOFLUOR II plate reader at an excitation wavelengthof 360 nm and an emission wavelength of 448 nm.

4.4 Screen for Factors that Enhance Proliferation of UndifferentiatedPSCs

This example describes a screen for identifying factors that enhance theproliferation of primate-derived primordial stem cells in anundifferentiated state using the cell growth conditions and alkalinephosphatase activity measurements described above.

4.4.1 Overview

PSC 43 cells were grown under four different conditions as described inSection 4.4.2 below. Cells grown under each of the four conditions wereplated in six wells of a 24-well microtiter plate. The four plated setsof cells were then exposed to one or more putative growth factors andthe effects of those putative factors on the growth of cells in anundifferentiated state was determined by measuring AP activity asdescribed in Section 4.2 above in a primary screen which is described inSection 4.4.3. Substances showing effectiveness in the primary screenwere then subjected to a confirmation screen in which the putativegrowth factor was tested against primate-derived primordial stem cellsas described in Section 4.4.4. Finally, growth factors showingeffectiveness in both screens were examined in duplicate and triplicatecombinations to investigate possible synergies among the factors asdescribed in Section 5.4.5.

Growth conditions 1 and 2 described in Sections 4.4.2.1 and 4.4.2.2below were used to examine the effects of putative growth factors on theproliferation of PSC43 cells in an undifferentiated state grown with andwithout a feeder later. Growth condition 3 described in Section 4.4.2.3below used a reduced serum concentration (2.5%) to slow down the growthof cells in view of the observation that PSC43 cells have extremely fastpopulation doubling time of 14-15 hours in growth medium containing 20%serum. Growth condition 4 described in Section 4.4.2.4 below wasdesigned to examine the effect of extracellular matrix (ECM) componentson the response of PSC43 cells to a putative growth factor, e.g., todetermine whether the ECM components sequester, block, or enhance theaction of a putative growth factor.

4.4.2 Growth Conditions

4.4.2.1 Growth Condition 1

One set of PSC 43 cells was grown using the method described in Section4.1 above using irradiated MEF cells that were prepared as follows. MEFcells were grown in a medium (“MEF medium”) that included DMEM mediumcontaining 10% fetal bovine serum (“FBS”) without antibiotics. Standard24-well tissue culture plates were coated with 0.5% gelatin overnight at37° C. The following day the cells were trypsinized, counted, andirradiated at 4,000 rads. The gelatin was removed from the plates, andthe irradiated cells were plated at a density of 100,000 cells/well as afeeder layer. The cells were allowed to attached to the wells overnightand about 25,000 PSC 43 cells per well were then plated over the cells.

4.4.2.2 Growth Condition 2

A second set of PSC 43 cells was grown using the method described inSection 4.1 on an extracellular matrix of STO or MEF cells. STO or MEFextracellular matrix was prepared as follows. Stock cultures of STO orMEF cells were grown in their respective media. Standard 24-well tissueculture plates were coated with 0.5% gelatin overnight at 37° C. afterwhich time the gelatin was removed from the wells. The STO or MEF cellswere trypsinized, counted, and plated in the wells at a density of about50,000 cells/well and allowed to grow to confluence. The cells were thenwashed once with 1 ml of PBS and lysed for a minimum of 10 minutes with0.5 ml of the above-described lysis buffer. The lysis buffer wasremoved, and the wells were washed three times with 1 ml of PBScontaining calcium and magnesium. About 0.5 ml of ES medium was thenadded to each well, and the plates were stored at 37° C. until platedwith PSC 43 cells as described above.

4.4.2.3 Growth Condition 3

A third set of PSC 43 cells was grown as described in Section 4.1 on theabove-described STO extracellular matrix using, however, 2.5% fetalbovine scrum in place of the 20% FBS described. Twenty-four hours afterplating of the cells, the medium was removed and fresh medium containingthe putative growth factor was added.

4.4.2.4 Growth Condition 4

A fourth set of PSC 43 cells was grown using several differentsubstances to determine an extracellular matrix (ECM) capable ofsupporting the proliferation of primate-derived primordial stem cells.

4.4.3 Primary Screen

Putative growth factor-containing medium was prepared as follows.Fifteen milliliters of ES medium were aliquoted into a 15 ml conicaltube. An aliquot of a stock solution containing the putative growthfactor was added and the combined solution was sterilized by filtrationthrough a 0.2 μm Acrodisc filter coupled with a 20 ml syringe. The finalconcentration of the growth factor solution was five-times the publishedmedian effective dose (ED₅₀), i.e., the dose that produces an observableresult in 50% of the treated cell population, for the putative growthfactor being tested. A summary of published ED50 values can be found inthe 1997 Cytokine Source Book from R&D Systems, Inc., Minneapolis, Minn.

The ES medium from each of the 24 wells of the plate being tested wasremoved by aspiration, and 1.5 ml of the above-described putative growthfactor-containing medium was added, in triplicate, to the wells. Sixwells were filled with a control solution made from ES medium containingPBS and 0.1% BSA. The control wells were chosen randomly on the plate toreduce the possibility of systematic errors. The PSC 43 cells wereallowed to incubate with the putative growth factor-containing mediumfor four days. The putative growth factor-containing medium was removedand replaced with fresh putative growth factor-containing medium at thesecond or third day.

On the fourth day, the cells were assayed for alkaline phosphataseactivity as described in Section 4.3. Substances differing from thecontrol by more or less than 20% of the control value were considered topromote the growth of undifferentiated PSC43 cells. A substance thatincreased the amount of alkaline phosphatase activity by more than 20%were in a substantially undifferentiated state.

Substances that showed activity as growth factors were examined in thesecondary screen described below. Those substances that demonstratedstrong differentiation promotion or suppression properties in bothscreens were examined using the tertiary screen directly.

Over 200 potential growth substances belonging to the EGF, FGF,Interleukin, TNF, LIF, GRO, NGF, Insulin-like, PDGF, the C—C Chemokinefamilies, as well as growth-factor-neutralizing antibodies, werescreened using the above-described protocol. In addition, the substancesangiogenin, anti-angiogenin, PD-ECGF, anti-PD-ECGF, TPO, anti-TPO, HGF,anti-HGF, CTLA4/F_(c) chimera, HCC-1, I-309, IP-10, MIG, SLPI,anti-SLPI, Strom CDF-1β, EPO, EPO soluble receptor, anti-EPO,Flt-1/F_(c) chimera80, Flt-3 ligand, anti-Flt-3 ligand, GCSF, anti-GCSF,GMCSF, anti-GMCSF, IFN-γ, anti-IFN-γ, leptin, MCSF, anti-MCSF, SCF,anti-SCF, ENA-78, and anti-ENA-78 were also screened. Substances thatincreased the amount of AP activity by more than 20% as compared to thecontrol were classified as promoters of undifferentiated cell growth.These substances are shown below in Table 2, which lists the promoterand the effect of the promoter on the growth of undifferentiated cellsas a percentage of the control. Substances that decreased the amount ofAP activity by more than 20% were classified as differentiationpromoters and are listed below in Table 3, which lists thedifferentiation promoter and the effect of the differentiation promoteron the growth of undifferentiated cells as a percentage of the control.The concentrations screened are in parentheses.

TABLE 2 Anti-TGF-β3 (0.6 μg/ml) Anti-PDGFbb (2.0 μg/ml) CNTF (15.0ng/ml) + Soluble CNTF Anti-TGF-β5 (100.0 ng/ml) Receptor (2.0 μg/ml)Anti-VEGF (0.16 μg/ml) Anti-TGF-β (20.0 μg/ml) MCP-1 (100.0 ng/ml) IL-17(30.0 ng/ml) IL-1α (35.0 pg/ml) IL-1β (50.0 pg/ml) Flt-3 Ligand (2.0ng/ml) Anti-IL-8 (20.0 μg/ml) Anti-BDNF (30.0 μg/ml) Anti-TNF-β (400.0ng/ml) IL-11 (1.2 ng/ml) IL-6 (4.0 ng/ml) LIF (1.0 ng/ml) Anti-HB-EGF(12.0 μg/ml) IL-6 (4.0 ng/ml) + Soluble IL-6 TGF-β LAP (200.0 ng/ml)Receptor (45.0 ng/ml) BFGF (1.25 ng/ml) FGF-4 (750.0 pg/ml) PDGF SolubleReceptor A (15.0 μg/ml) Forskolin (10.0 μg/ml) Dexamethasone

TABLE 3 PDGF (15.0 ng/ml) PDGFaa (25 ng/ml) PDGFab (15.0 ng/ml) PDGFbb(15.0 ng/ml) HB-EGF (25.0 ng/ml) TGF-α (2.0 ng/ml) TGF-β1 (300.0 pg/ml)EGF (2.0 ng/ml) Betacellulin (1.5 ng/ml) TGF-α1.2 (400.0 pg/ml) TNF-β(250.0 pg/ml) TNF-α (250.0 pg/ml) TGF-β2 (1.0 ng/ml) TGF-β3 (150.0pg/ml) Anti-CNTF (120.0 μg/ml) RANTES (1.0 μg/ml)

4.4.4 Confirmation Screen

Factors that demonstrated effect in the primary and secondary screenswere screened in a tertiary screen using Rhesus ES cells to confirm theresults of the earlier screens. Rhesus ES cells were grown as follows.Eight to ten colonies of the cells were picked, dissociated, pelleted,and resuspended in about 24 ml of ES medium. About 1 ml of the cellsuspension was added to each well of a feeder-coated 24-well plate. Theplated cells were left overnight.

About 1.5 ml of growth factor- or control-containing ES medium, preparedas described above, was added to each of the wells. The cells were leftto grow for six days in the presence of the growth factor(s) duringwhich time the medium was replaced on days two and four. The cells werethen allowed to grow for two more days at which time they were testedfor AP activity. The number and size of the Rhesus cell colonies wasnoted and compared with the number and size of the control colonies. Ifthe numbers and sizes of the control colonies were consistent with thedegree of AP activity observed, then the results of the confirmationscreen were considered consistent with the results of the primaryscreen.

4.4.5 Screen for Synergistic Effects

Growth factors that demonstrated effects in all assays are included induplex and triplex screens to determine the presence of any synergisticeffects among the growth factors. These screens are run as describedabove with the exception that two- and three-way combinations of thosegrowth substances identified by at least the primary and confirmationscreens as active are used in place of individual growth factors.Combinations that provide superior qualities as compared the qualitiesof the individual components will be included as media supplements.

4.5 Screen for Extracellular Matrix Components for Feeder-free Growth ofPrimate-derived Primordial Stem Cells

The above-described PSC 43 cells were grown on a defined matrix ofselected extracellular materials. The PSC 43 cells were plated in thewells of 24-well plates that had been coated with one of the followingsubstances: collagen II, collagen III, collagen IV, collagen V, preparedextracellular matrix (partially purified matrix extract of humanplacenta, available commercially from SIGMA), fibronectin, laminin,merosin (laminin homolog), tenascin, heparan sulfate, chondroitinsulfate, dermatan sulfate, aggrecan, biglycan, thrombospondin,vitronectin, or decorin. Cells were also plated in wells that had beencoated with one of the listed substance and gelatin, alone or incombination with fibronectin. Cells were grown for about 6 days at whichtime the growth of cells remaining in an undifferentiated state wasmeasured. The growth of PSC43 cells in an undifferentiated state usingthese substances and combinations was measured by determining theexpression of alkaline phosphatase as described in Section 4.2 above andcompared to the growth of PSC43 cells in control wells on STO cells.

The results of the screen are provided in Table 4, below. Substancesand/or combinations that provided an increase in AP activity of greaterthan about 20% as compared to the control were determined to be positivefactors for feeder-free growth of primate-derived primordial stem cells.As seen from the data in Table 4, merosin, merosin combined withgelatin, and all combinations of collagen II and heparan sulfate werefound to be positive factors for feeder-free growth of primate-derivedprimordial stem cells. The concentration of the putative matrixcomponent being screened is provided in parentheses.

TABLE 4 Growth of Undifferentiated PSC 43 Putative Matrix ComponentCells as a Percentage of Control Merosin (10.0 μg/cm²) 233 Collagen II(10.0 μg/cm²) 227 Heparan Sulfate (3.0 μg/cm²) 206 Gelatin (0.5%) 180Fibronectin (5.0 μg/cm²) 146 Tenasin (10.0 μg/cm²) 128 Dermatan Sulfate(3.0 μg/cm²) 128 Collagen IV (1.0 μg/cm²) 126 Collagen III (1.0 μg/cm²)126 Vitronectin (50.0 ng/cm²) 126 Decorin (10.0 μg/cm²) 125

4.6 Growth Conditions for Enhancing the Maintenance of UndifferentiatedPSCs

The Example demonstrates the addition of anti-retinoic antibodies in thegrowth medium of primate-derived primordial stem cells to enhance growthof such cells in an undifferentiated state.

PSC43 cells (at passage number 17, post-feeder) were plated onto dishescoated with a fibroblast matrix prepared from lysed fibroblasts andconditioned medium as described above. The cells were maintained using agrowth medium containing DMEM with 4.5 g/L glucose, 0.1 mM non-essentialamino acids, 0.1 mM β-mercaptoethanol and 20% fetal bovine serum whichhad been conditioned as described above. This medium was supplementedwith anti-retinoic acid antibodies at final concentrations of either 1μg/ml or 10 μg/ml. The antibodies had been prepared as described in Zhoeet al., 1991 J. Nutr. Biochem. 2:122-131 and Zhoe et al., 1991 J.Immunol. Methods 138:211-223. A control was also prepared in which PSC43 cells were grown in the same medium as just described but withoutanti-retinoic acid antibodies.

The AP levels of the cells were measured as described above after oneweek in culture. A 27% increase in AP activity was observed in thosecultures that had been supplemented with anti-retinoic acid antibodies.Addition of anti-retinoic acid antibodies at either 1 μg/ml or 10 μg/mlprovided the same effect. These results indicate that conditioned ESmedium including anti-retinoic acid antibodies enhances the growth ofundifferentiated primate-derived primordial stem cells.

4.7 Determination of Telomerase Activity in Primate-derived PSCs

This Example illustrates the detection of telomerase activity inprimate-derived primordial stem cells as a marker for undifferentiationin such cells.

Cell extracts of undifferentiated rhesus monkey primordial stem cells,differentiated Rhesus monkey primordial stem cells, mouse embryonicfibroblast cells, and 293 cells were prepared by a modification of thedetergent lysis method described by Kim, et al., (Science 266:2011 1994)in which the cells were washed with phosphate buffered saline and lysedwith CHAPS lysis buffer for 30 minute on ice. The MEF, differentiatedcell, and undifferentiated ES cell extracts were prepared atconcentrations of 10,000 cells/μl of CHAPS lysis buffer, 20,000 cells/μlof CHAPS lysis buffer, and approximately 1,000 cells/μl of CHAPS lysisbuffer, respectively. The control, telomerase-positive 293 cell extract(an adenovirus-transformed human kidney cell line) was prepared at 1,000cells/ml in CHAPS lysis buffer. The lysed cells were centrifuged at12,000 g for 30 minutes at 4° C. and the cell extracts (thesupernatants) were removed.

Telomerase activity in the cell extracts was determined using a modifiedPCR-based TRAP assay. A modified reverse primer (RP,5′-GCGCGG(CTTACC)₃CTAACC-3′, SEQ. ID NO:1) and a ³²p end-labeled forwardprimer (TS, 5′-AATCCGTCGAGCAGAGTT-3′, SEQ. ID NO:2) were synthesizedusing standard methods and materials. Two μl of each cell extract werecombined with 48 μl of a mixture containing 20 mM Tris-HCl (pH 8.3), 1.5mM MgCl₂, 63 mM KCl, 0.05% Tween 20, 1 mM EGTA, 0.1 mg/ml bovine serumalbumin (BSA, fraction V, purchased from Boehringer Mannheim), 2 μg/mlTS, 2 mg/ml RP, 50 μM each of dATP, dCTP, dTTP, dGTP and 0.04 Units/μlTaq polymerase. PCR amplification was performed for 27 cycles, eachcycle being a sequence of amplification at a temperature of 94° C. for30 seconds, 60° C. for 30 seconds, and 72° C. for 30 seconds. FollowingPCR, the samples were resolved by polyacrylamide gel electrophoresis ona 15% non-denaturing polyacrylamide gel. The gels were dried and theproducts visualized using a phosphorimager. A control sample containing0.2 units of RNase for each cell extract was also prepared and analyzed.Quantitation of the PCR products was conducted by comparing signals fromserial dilutions of cell extracts to those from serial dilutions oftelomerase-expressing 293 cells. The cell extracts had been normalizedfor protein concentration. Protein determination was done using theCoomassie Protein Assay Reagent (Pierce #23200) using BSA as standard.

Undifferentiated Rhesus monkey ES cells showed high levels of telomeraseactivity, whereas feeder and differentiated rhesus monkey cells had nodetectable telomerase activity. The undifferentiated Rhesus monkey EScells also demonstrated greater than 2.5-fold level of telomeraseactivity compared with 293 cells. A comparable level of cell extractfrom MEF cells showed very faint or no detectable telomerase signals.The latter result also demonstrated that the observed telomerase signalin the undifferentiated Rhesus primordial stem cells did not arise fromcontamination of the sample of undifferentiated Rhesus cells by MEFcells.

5 Conclusion

Thus, the present invention provides novel materials and methods forgrowing primate-derived primordial stem cells in a substantiallyundifferentiated state. Using the methods and materials provided the,present invention primate-derived primordial stem cells, such asprimordial stem cells isolated from humans and monkeys, can be grownmore efficiently. The ability to grow efficiently such cells withoutdifferentiation has important applications for therapeutic uses ofprimordial stem cells for treating human diseases using tissuetransplantation and/or gene therapy techniques where such cells are useddirectly or following one or more genetic modifications as describedherein. In addition, primate-derived primordial stem cells grown usingthe methods and materials described herein can be used to screen for newbioactive substances or for other factors that promote or retard thedifferentiation of such cells in culture.

2 1 30 DNA Homo sapiens 1 gcgcggctta cccttaccct taccctaacc 30 2 18 DNAHomo sapiens 2 aatccgtcga gcagagtt 18

What is claimed:
 1. A cellular composition comprising undifferentiatedprimate primordial stem (pPS) cells proliferating on an extracellularmatrix, wherein the composition is free of feeder cells.
 2. Thecomposition of claim 1, wherein the extracellular matrix is a fibroblastmatrix, prepared by culturing fibroblasts, lysing the fibroblasts insitu, and then washing what remains after lysis.
 3. The composition ofclaim 1, wherein the extracellular matrix is prepared from a matrixcomponent or combination of such components.
 4. The composition of claim3, wherein the extracellular matrix is prepared from an isolated matrixcomponent or a combination of components selected from collagen,placental matrix, fibronectin, laminin, merosin, tenascin, heparinsulfate, condroitin sulfate, dermatan sulfate, aggrecan, biglycan,thrombospondin, vitronectin, and decorin.
 5. The composition of claim 1,further comprising a nutrient medium.
 6. The composition of claim 5,wherein the nutrient medium comprises sodium pyruvate and nucleosides,and has a low endotoxin level.
 7. The composition of claim 5, whereinthe nutrient medium comprises one or more exogenously added factors thatpromote undifferentiated growth of primordial stem cells, selected fromTGF-β, IL-11, IL-6, IL-6 receptor, IL-1, LIF, IL-17, LAP, MCP-1, bFGF,FGF-4, PDGF soluble receptor A, forskolin, and antibodies to IL-8,TGF-β, BDNF, TNF-β, VEGF, and EGF.
 8. The composition of claim 5,wherein the nutrient medium is a conditioned medium.
 9. The compositionof claim 8, wherein the conditioned medium is obtained by collectingmedium from a culture of growing feeder cells.
 10. The composition ofclaim 1, wherein the pPS cells have been genetically altered; or are theundifferentiated progeny of genetically altered cells.
 11. Thecomposition of claim 10, wherein the pPS cells have been geneticallyaltered by introducing a gene encoding either the RNA component oftelomerase, or telomerase reverse transcriptase (hTRT); or are theundifferentiated progeny of such cells.
 12. The composition of claim 1,wherein the undifferentiated pPS cells have been obtained from ablastocyst.
 13. A composition comprising: a) a substrate comprising anextracellular matrix; b) a conditioned medium; and c) proliferatingundifferentiated primate primordial stem (pPS) cells; wherein thecomposition is essentially free of feeder cells.
 14. A cellularcomposition comprising undifferentiated pPS cells proliterating on anextracellular matrix, obtained by passaging pPS cells cultured on feedercells to a new growth environment having an extracellular matrix butfree of feeder cells; and then culturing the pPS cells in the new growthenvironment such that they proliferate without differentiating.
 15. Thecomposition of claim 14, wherein the extracellular matrix is afibroblast matrix, prepared by culturing fibroblasts, lysing thefibroblasts in situ, and then washing what remains after lysis.
 16. Thecomposition of claim 14, wherein the extracellular matrix is preparedfrom a matrix component or combination of such components.
 17. Thecomposition of claim 14, wherein the growth environment comprises one ormore exogenously added factors that promote undifferentiated growth ofprimordial stem cells, selected from TGF-β, IL-11, IL6, IL-6 receptor,IL-1, LIF, IL-17, LAP, MCP-1, bFGF, FGF4, PDGF soluble receptor A,forskolin, and antibodies to IL-8, TGF-β, BDNF, TNF-β, VEGF, and EGF.18. The composition of claim 14, wherein the growth environmentcomprises a medium that has been conditioned by culturing with feedercells.
 19. The composition of claim 14, wherein the wherein the growthenvironment comprises added fibroblast growth factor.
 20. Thecomposition of claim 14, wherein the undifferentiated pPS cells havebeen obtained from a blastocyst.
 21. A cell population consistingessentially of primate embryonic stem (ES) cells proliferating inculture on an extracellular matrix in a manner such that at least 50% ofthe proliferating ES cells are undifferentiated.
 22. The cell populationof claim 21, wherein the extracellular matrix is a fibroblast matrix,prepared by culturing fibroblasts, lysing the fibroblasts in situ, andthen washing what remains after lysis.
 23. The cell population of claim21, wherein the extracellular matrix is prepared from a matrix componentor combination of such components.
 24. The cell population of claim 21,in a nutrient medium that comprises one or more exogenously addedfactors that promote undifferentiated growth of primordial stem cells,selected from TGF-β, IL-11, IL-6, IL-6 receptor, IL-1, LIF, IL-17, LAP,MCP-1, bFGF, FGF-4, PDGF soluble receptor A, forskolin, and antibodiesto IL-8, TGF-β, BDNF, TNF-β, VEGF, and EGF.
 25. The cell population ofclaim 21, in a medium that has been conditioned by culturing with feedercells.
 26. The cell population of claim 21, wherein the undifferentiatedES cells are positive for SSEA-4, TRA-1-60, or TRA-1-81.
 27. The cellpopulation of claim 21, wherein the undifferentiated ES cells havealkaline phosphatase activity.
 28. The cell population of claim 21,wherein the undifferentiated ES cells have telomerase enzymaticactivity.
 29. The cell population of claim 21, wherein the ES cells arehuman embryonic stem cells.
 30. A cellular composition comprisingundifferentiated human embryonic stem cells proliferating on anextracellular matrix, wherein the composition is free of feeder cells.31. The composition of claim 30, wherein the extracellular matrix is afibroblast matrix, prepared by culturing fibroblasts, lysing thefibroblasts in situ, and then washing what remains after lysis.
 32. Thecomposition of claim 30, wherein the extracellular matrix is preparedfrom a matrix component or combination of such components.
 33. Thecomposition of claim 32, wherein the extracellular matrix is preparedfrom an isolated matrix component or a combination of componentsselected from collagen, placental matrix, fibronectin, laminin, merosin,tenascin, heparin sulfate, condroitin sulfate, dermatan sulfate,aggrecan, biglycan, thrombospondin, vitronectin, and decorin.
 34. Thecomposition of claim 30, further comprising a nutrient medium.
 35. Thecomposition of claim 34, wherein the nutrient medium comprises sodiumpyruvate and nucleosides, and has a low endotoxin level.
 36. Thecomposition of claim 34, wherein the nutrient medium comprises one ormore exogenously added factors that promote undifferentiated growth ofprimordial stem cells, selected from TGF-β, IL-11, IL-6, IL-6 receptor,IL-1, LIF, IL-17, LAP, MCP-1, bFGF, FGF-4, PDGF soluble receptor A,forskolin, and antibodies to IL-8, TGF-β, BDNF, TNF-β, VEGF, and EGF.37. The composition of claim 34, wherein the nutrient medium is aconditioned medium.
 38. The composition of claim 37, wherein theconditioned medium is obtained by collecting medium from a culture ofgrowing feeder cells.
 39. A cellular composition comprisingundifferentiated human embryonic stem (ES) cells proliferating on anextracellular matrix, obtained by passaging human ES cells cultured onfeeder cells to a new growth environment having an extracellular matrixbut free of feeder cells; and then culturing the ES cells in the newgrowth environment such that they proliferate without differentiating.40. The composition of claim 39, wherein the extracellular matrix is afibroblast matrix, prepared by culturing fibroblasts, lysing thefibroblasts in situ, and then washing what remains after lysis.
 41. Thecomposition of claim 39, wherein the extracellular matrix is preparedfrom a matrix component or combination of such components.
 42. Thecomposition of claim 39, wherein the growth environment comprises one ormore exogenously added factors that promote undifferentiated growth ofprimordial stern cells, selected from TGF-β, IL-11, IL-6, IL-6 receptor,IL-1, LIF, IL-17, LAP, MCP-1, bFGF, FGF-4, PDGF soluble receptor A,forskolin, and antibodies to IL-8, TGF-β, BDNF, TNF-β, VEGF, and EGF.43. The composition of claim 39, wherein the growth environmentcomprises a medium that has been conditioned by culturing with feedercells.
 44. The composition of claim 39, wherein the wherein the growthenvironment comprises added fibroblast growth factor.